KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Total Non-Current Liabilities: 2009-2024

Historic Total Non-Current Liabilities for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Dec 2024 value amounting to $1.2 billion.

  • Biomarin Pharmaceutical's Total Non-Current Liabilities rose 6.47% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year increase of 6.47%. This contributed to the annual value of $1.2 billion for FY2024, which is 32.09% down from last year.
  • Biomarin Pharmaceutical's Total Non-Current Liabilities amounted to $1.2 billion in FY2024, which was down 32.09% from $1.8 billion recorded in FY2023.
  • In the past 5 years, Biomarin Pharmaceutical's Total Non-Current Liabilities ranged from a high of $1.8 billion in FY2023 and a low of $1.2 billion during FY2024.
  • Moreover, its 3-year median value for Total Non-Current Liabilities was $1.7 billion (2022), whereas its average is $1.5 billion.
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first climbed by 10.77% in 2020, then crashed by 32.09% in 2024.
  • Biomarin Pharmaceutical's Total Non-Current Liabilities (Yearly) stood at $1.6 billion in 2020, then climbed by 0.79% to $1.6 billion in 2021, then rose by 1.90% to $1.7 billion in 2022, then grew by 5.87% to $1.8 billion in 2023, then slumped by 32.09% to $1.2 billion in 2024.